Long-Term Efficacy of ALA Photodynamic Therapy of AKs

Abstract

Topical aminolevulinic acid photodynamic therapy (ALA-PDT) has been approved by the FDA for the treatment of actinic keratoses (AKs) of the face and scalp. Treatment involves application of aminolevulinic acid to the lesions, followed 18 hours later by exposure to 417-nm blue light. Although this therapy has been shown to produce short-term regression of thin to moderately thick AKs, the long-term efficacy has not been determined. Investigators in …